Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis

Effectiveness of Janus kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis

Aim. To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods. Randomized controlled trials of tofacitinib, baricitinib and upadacitinib i...

Full description

Bibliographic Details
Main Authors:	A. E. Cheberda, D. Yu. Belousov
Format:	Article
Language:	Russian
Published:	Izdatelstvo OKI 2024-02-01
Series:	Качественная клиническая практика
Subjects:	ревматоидный артрит тофацитиниб барицитиниб упадацитиниб ингибиторы янус-киназ систематический обзор метаанализ haq-di acr20
Online Access:	https://www.clinvest.ru/jour/article/view/693

Similar Items

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patients with rheumatoid arthritis
by: E. V. Chetina, et al.
Published: (2021-06-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation
by: A. M. Lila, et al.
Published: (2020-09-01)

A Russian version of AMSTAR 2: validation and guidance
by: D. V. Kvashnina, et al.
Published: (2022-07-01)

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
by: A. E. Karateev, et al.
Published: (2020-05-01)

Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
by: O. V. Shatalova, et al.
Published: (2017-04-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
by: G. V. Lukina, et al.
Published: (2015-12-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis
by: A. S. Kolbin, et al.
Published: (2020-05-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Hypermetropia as a Risk Factor for Age-Related Macular Degeneration. Review
by: V. G. Likhvantseva, et al.
Published: (2022-07-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
by: A. S. Kolbin, et al.
Published: (2022-05-01)

Patient's reported outcomes – a new philosophy for analyzing the effectiveness of therapy in immunoinflammatory diseases
by: article Editorial
Published: (2021-10-01)

Длительный интермиттирующий гемодиализ как альтернатива постоянной заместительной почечной терапии в лечении острого почечного повреждения: систематический обзор и метаанализ
by: З. М. Унароков, et al.
Published: (2016-03-01)

ПРИМЕНЕНИЕ МЕТОДА МЕТААНАЛИЗА В ГУМАНИТАРНЫХ И ПЕДАГОГИЧЕСКИХ ИССЛЕДОВАНИЯХ
by: Донской Алексей Геннадьевич, et al.
Published: (2021-01-01)

Features of the subpopulation composition of dendritic cells in patients with rheumatoid arthritis
by: M. A. Korolev, et al.
Published: (2019-09-01)

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
by: S. K. Zyryanov, et al.
Published: (2023-07-01)

Clinical and laboratory differences between primary acute and reactivation of chronic Epstein-Barr viral infection in children (systematic review and meta-analysis)
by: M. M. Kulikova, et al.
Published: (2022-03-01)

CYCLOSPORINE A IN RHEUMATOID ARTHRITIS: CURRENT DATA
by: Elena Lvovna Luchikhina
Published: (2009-09-01)

Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
by: Yaqi Kang, et al.
Published: (2019-08-01)

Methodology of Writing Literature Review on Management and Business: Digest of Overseas Highly-Cited Articles
by: I. V. Denisov
Published: (2021-12-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB
by: Evgeni Lvovich Nasonov
Published: (2009-12-01)

SECONDARY AMYLOIDOSIS WITH LUNG INVOLVEMENT INA FEMALE PATIENT WITH RHEUMATOID ARTHRITIS
by: Irina Mikhailovna Marusenko, et al.
Published: (2009-09-01)

Certolizumab pegol in therapy for rheumatoid arthritis
by: Galina Viktorovna Lukina, et al.
Published: (2012-06-01)

Efficiency and safety of leflunomide in rheumatoid arthritis: Results of a Russian observational multicenter of trial
by: R. M. Balabanova, et al.
Published: (2015-06-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

Efficiency of orthotic intervention in the rehabilitation of patients with rheumatoid arthritis
by: E. V. Orlova, et al.
Published: (2016-09-01)

Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
by: G. A. Markova, et al.
Published: (2022-10-01)

Antikeratin antibodies in rheumatoid arthritis
by: J Zabek
Published: (2003-02-01)

Specific features of comorbidity in rheumatoid arthritis patients in different follow-up years
by: N. M. Nikitina, et al.
Published: (2015-03-01)

THE ROLE OF VITAMINS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Zh. V. Maximova, et al.
Published: (2017-05-01)

Interstitial lung involvement in rheumatoid arthritis
by: David Vladimirovich Bestaev, et al.
Published: (2014-12-01)

Causal Therapy of COVID-19: Critical Review and Prospects
by: N. V. Beloborodova, et al.
Published: (2020-12-01)